Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Coherus BioSciences Inc

CHRS
Current price
2.3 USD +0.17 USD (+7.98%)
Last closed 2.13 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 229 409 840 USD
Yield for 12 month -66.81 %
Week
Month
Year
CHRS
21.11.2021 - 28.11.2021

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Address: 333 Twin Dolphin Drive, Redwood City, CA, United States, 94065

Analytics

WallStreet Target Price

11 USD

P/E ratio

Dividend Yield

Current Year

+211 042 000 USD

Last Year

+326 551 000 USD

Current Quarter

+74 568 000 USD

Last Quarter

+58 716 000 USD

Current Year

+140 959 000 USD

Last Year

+268 960 000 USD

Current Quarter

+41 865 000 USD

Last Quarter

+33 868 000 USD

Key Figures CHRS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -150 508 992 USD
Operating Margin TTM -4.57 %
PE Ratio
Return On Assets TTM -17 %
PEG Ratio
Return On Equity TTM -1657.06 %
Wall Street Target Price 11 USD
Revenue TTM 211 072 000 USD
Book Value -1.22 USD
Revenue Per Share TTM 2.46 USD
Dividend Share
Quarterly Revenue Growth YOY 64.2 %
Dividend Yield
Gross Profit TTM -58 399 000 USD
Earnings Share -2.55 USD
Diluted Eps TTM -2.55 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY -75.5 %
Profit Margin -102.86 %

Dividend Analytics CHRS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CHRS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CHRS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 32.8947
Enterprise Value Revenue 3.2024
Price Sales TTM 2.3539
Enterprise Value EBITDA -3.1091
Price Book MRQ 73.1897

Financials CHRS

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CHRS

For 52 weeks

1.43 USD 10.99 USD
50 Day MA 3.22 USD
Shares Short Prior Month 18 724 561
200 Day MA 5.08 USD
Short Ratio 5.17
Shares Short 19 838 260
Short Percent 21.35 %